Compass Therapeutics Reports 2025 Financial Results, Promotes Bing Gong to CSO, and Announces Expansion of Phase 1 Study of CTX-8371.

Compass Therapeutics reported 2025 financial results, highlighting the Phase 2/3 COMPANION-002 study of tovecimig in biliary tract cancer, which reached the prespecified event threshold of 80% overall survival events in Q1 2026. The company also promoted Bing Gong to Chief Scientific Officer and expects to report progression-free survival and overall survival data in April. Additionally, Compass Therapeutics has expanded cohorts for CTX-8371 in triple-negative breast cancer and non-small cell lung cancer, and received FDA clearance for CTX-10726, which will begin Phase 1 enrollment in Q1. The company has $209 million in cash and marketable securities, funding operations into 2028.